| Ytd | 291.92% | |
| 1y | 179.53% |
| Open | 50.23 | Prev Close | 49.98 | Low | 50.23 | High | 53.97 | Mkt Cap | 3.84B |
| Vol | 367.60K | Avg Vol | 502.81K | EPS | -1.18 | P/E | N/A | Forward P/E | -45.99 |
| Beta | 1.57 | Short Ratio | 5.23 | Inst. Own | 15.42% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 48.22 | 200-d Avg | 28.43 | 1yr Est | 56.50 |
PLSE News
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its n
Canaccord Genuity analyst William Plovanic maintains Pulse Biosciences (NASDAQ:PLSE) with a Buy a
Shares of Pulse Biosciences, Inc (NASDAQ: PLSE - Get Free Report) have been given a consensus rating
U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securit
Analysts initiated bullish coverage on HCA, GRDN, TTC, MRVL and PLSE, setting price targets of $495,
BTIG analyst Marie Thibault initiates coverage on Pulse Biosciences (NASDAQ:PLSE) with a Buy rati
On September 15, 2026, Pulse Biosciences, Inc. (the "Company") entered into an equity distri
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse⢠technology using proprietar
Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary N
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPu
U.S. stocks fell, but Wealthfront surged 6.6% after beating Q2 earnings and revenue estimates; Orche
An analyst initiated coverage with an unambiguous buy recommendation. He feels that one market in pa
Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regula
Freedom Capital Markets analyst Keith Hinton initiates coverage on Pulse Biosciences (NASDAQ:PLSE
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its n
Deutsche Bank AG purchased a new stake in Pulse Biosciences, Inc (NASDAQ: PLSE) in the second quarte
As of Aug. 27, 2026, three health care stocks are overbought and could be giving a real warning to m
Bank of America Corp DE raised its holdings in shares of Pulse Biosciences, Inc (NASDAQ: PLSE) by 8.
Pulse Biosciences, Inc (NASDAQ: PLSE - Get Free Report) shares reached a new 52-week high during tra
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its n
Top Wall Street analysts changed their outlook on top stocks. See analyst ratings and price targets
WALL analysts changed outlook on top names. See upgrades, downgrades & initiations on analyst ra
Top Wall Street analysts changed outlook on top names. See analyst rating changes on Benzinga's
Needham analyst Mike Matson initiates coverage on Pulse Biosciences (NASDAQ:PLSE) with a Buy rati
Pulse Biosciences NASDAQ: PLSE is positioning its nanosecond pulsed field ablation technology as a p
Canaccord Genuity analyst William Plovanic maintains Pulse Biosciences (NASDAQ:PLSE) with a Buy a
Pulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call Transcript
Pulse Biosciences NASDAQ: PLSE reported second-quarter revenue of $434,000 as it accelerated clinica
Pulse Biosciences, Inc (PLSE) came out with a quarterly loss of $0.36 per share versus the Zacks Con
Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.36) per share which met the analyst
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its n
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its n
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its n
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its n
Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected f
Canaccord Genuity analyst William Plovanic initiates coverage on Pulse Biosciences (NASDAQ:PLSE)
Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of nPulse™ technology using proprietary nanosecond
Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.27) per share which beat the analys
The first seven patients in this study were treated at St. Bernards Medical Center in Jonesboro, Ark
Pulse Biosciences, Inc. (NASDAQ:PLSE), pioneer of the novel nPulse™ platform using proprietary Nanos
Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using its proprieta
Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.26) per share which beat the analys
Pulse Biosciences stock rises after new study data showed strong early results for its heart treatme